Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
What is the purpose of this trial?
This study will investigate the effects of the combination of bosentan and sildenafil versus sildenafil alone on time to first morbidity/mortality event in patients with symptomatic PAH. Patients must be receiving sildenafil equal to or greater tha 20 mg t.i.d. for at least 12 weeks prior to being randomized to receive either bosentan 125 mg b.i.d. or matching placebo. The study will continue until the predefined target number of morbidity/mortality events is reached.
- 12 Years and older
- April 2006
- Last Updated:
- August 30, 2013
- Study HIC#:
Clinicaltrials.gov ID: NCT00303459